Giulia T.
- Country
- Italy
- Department
- Oncologia 2
Research Overview
- Phase 3 Randomized Open‑Label Study of INCB123667 Versus Investigator’s Choice Chemotherapy Combination in Platinum‑Resistant Ovarian Cancer with Cyclin E1 Overexpression
- Evaluation of Palonosetron and Netupitant as Antiemetic Therapy in Chemotherapy-Naïve Endometrial Cancer Patients Receiving Paclitaxel-Carboplatin Regimen.
- Phase III Randomized Trial of Platinum-Based Chemotherapy with Paclitaxel, Bevacizumab, and Atezolizumab in Metastatic, Persistent, or Recurrent Cervical Carcinoma
Data & Insights
Has run more than one trial at 138 of 311 partner sites.
Specializations
Gynecologic Oncology Focus
This investigator specializes in treating various forms of gynecologic cancers, with particular emphasis on ovarian cancer and its advanced manifestations including fallopian tube cancer and primary peritoneal cancer.
- Advanced epithelial ovarian cancer management
- Endometrial cancer treatment
- Cervical carcinoma therapy
Their expertise extends to treating both initial diagnoses and recurrent cases.
Treatment Approaches
The investigator works with innovative therapeutic combinations including maintenance therapy strategies and targeted treatments. Their work encompasses both traditional and emerging treatment modalities.
- Combined chemotherapy protocols
- Immunotherapy integration
- Anti-angiogenic therapy
Special focus is placed on developing treatment strategies for patients with specific genetic profiles.
Specialized Therapeutic Areas
The investigator has particular interest in DNA repair mechanisms and their role in cancer treatment, especially concerning homologous recombination deficiency.
- PARP inhibitor applications
- Antiemetic treatment protocols
- Secondary cytoreductive surgery outcomes
Their work includes evaluation of treatment efficacy in various clinical scenarios.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.